Selecta Biosciences Inc
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.Selecta Biosciences Inc is a clinical-stage biopharmaceutical company using its proprietary synthetic vaccine particle technology to discover and develop targeted therapies designed to modulate the immune system to treat rare and serious diseases.
Latest SELB News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News